| 0.761 0 (0%) | 12-01 15:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.96 | 1-year : | 2.75 |
| Resists | First : | 1.68 | Second : | 2.36 |
| Pivot price | 0.83 |
|||
| Supports | First : | 0.57 | Second : | 0.48 |
| MAs | MA(5) : | 0.78  |
MA(20) : | 0.82 |
| MA(100) : | 2.4 |
MA(250) : | 2.23 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 37.8 |
D(3) : | 38.2 |
| RSI | RSI(14): 32.5 |
|||
| 52-week | High : | 6.9 | Low : | 0.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CWBR ] has closed above bottom band by 45.8%. Bollinger Bands are 61.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.74 | 0.74 - 0.75 |
| Low: | 0.64 - 0.64 | 0.64 - 0.65 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Thu, 30 Nov 2023
CohBar, Inc.(OTCPK : CWBR) dropped from S&P TMI Index - Marketscreener.com
Tue, 28 Nov 2023
Why SenesTech Shares Are Trading Lower By Around 50%? Here ... - Investing.com UK
Tue, 28 Nov 2023
Why SpringWorks Shares Are Trading Higher By Around 14%; Here ... - MSN
Tue, 28 Nov 2023
North American Morning Briefing : November Rally Pauses Ahead of ... - Marketscreener.com
Mon, 27 Nov 2023
2023-11-27 | PINL:CWBR | Press Release | CohBar Inc - Stockhouse Publishing
Thu, 02 Nov 2023
U.S. shares higher at close of trade; Dow Jones Industrial Average ... - Investing.com Australia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 29 (K) |
| EPS | -4.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.4 % |
| Return on Equity (ttm) | -84 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|